Register Now

Safeguard your patient’s surgery with Leukomed® Sorbact®

Surgical Site Infections (SSIs) are generally considered avoidable harms that can be prevented with appropriate care; Leukomed Sorbact has demonstrated proven effectiveness in reducing the risk in various clinical studies 1 2

SSI’s are costly, increasing the readmission rate by a factor of five and doubling mortality rates3. 15% of the world’s antibiotics are used to prevent SSI4, but they still occur and other prevention strategies are necessary. The typical average cost of SSI is estimated to be more than £10,000 per episode; deep infections associated with joint replacement surgery present a staggering £100,000 added costs per patient5. Using evidence based measures, 60% of SSis could be prevented6. Reducing SSI rates can reduce readmissions, antibiotic use, offer cost savings and benefit patient quality of life7.

Using Leukomed Sorbact post operatively can reduce SSI risk in patients post caesarean section by up to 67% versus standard of care1 , 7, and by up to 47% in patients post vascular surgery8.

In addition, the evidence reviewed suggests that Leukomed Sorbact:

  • Reduces SSI in caesarean section and vascular surgery
  • May reduce antibiotic use
  • May reduce readmissions from wound complications

Cost savings are anticipated as Leukomed Sorbact is expected to reduce re-admissions and shorten the length of stay in hospital. For more details see the NICE resource impact report*9.

NHSSC publish value-based procurement caesarean section case study

NHSSC have a released a case study from Barking, Havering, and Redbridge University hospitals NHS Trust (BHRUT) where the standard non-woven dressing was replaced with a Leukomed Sorbact wound dressing following all caesarean sections.

  • A 37.7% drop in the rate of SSI (p<0.05)
  • Reduction in SSI-related readmissions by 29.4% (rate) and 38.8% (days when admitted)
  • A 30.4% decrease in antibiotic usage for women readmitted with a SSI
  • BHRUT saved £49,750 on wound care alone (using PLICS data) and £234,784 in associated system wide costs (the total cost of care).

To read the full NHSSC Case Study go to: www.supplychain.nhs.uk/news-article/sorbact-film-dressing-improves-patient-experience/

Leukomed Sorbact

Leukomed Sorbact is an interactive dressing that binds to the microbes that cause surgical site infections, so they are removed when the dressing is changed. It is intended for use in management of contaminated, colonised or infected dry to low-exuding wounds, such as surgical wounds and traumatic wounds, e.g. lacerations, cuts and abrasions.

Product benefits

Bacteria and fungi-binding: This dressing is coated with a hydrophobic fatty acid ester which attracts microorganisms and are removed with each dressing change.

Reduced risk of infection: Prophylactic use of Leukomed Sorbact reduces the risk of infections.

Low allergy risk: This surgical wound dressing has a low allergy risk; in accordance with ISO 10993.

Protects from bacteria and microorganisms: The innovative design makes Sorbact effective against antibiotic-resistant microorganisms; fungi; and different types of bacteria.

Manages dry to low exuding wounds: Well suited to postoperative and traumatic dry to low-exuding wounds including surgical incisions; lacerations; cuts and abrasions; dehisced wounds; and minor burns.

Sterile: Leukomed Sorbact is delivered sterile.

CLICK HERE FOR MORE PRODUCT INFO

Sorbact Technology Mode of Action

Sorbact Technology effectively prevents and treats wound infection across all ages, from children to the elderly. Developed with a physical mode of action, bacteria irreversibly bind to the DACC™-coated surface and are safely removed. Evidence has shown an antibacterial effect without the release of active substances, and therefore antimicrobial resistance is not expected. Sorbact Technology dressings deliver powerful, safe and effective wound infection management for the advancement of patient well-being.

References:

  1. Stanirowski J, Bizon M, Cendrowski K, et al (2016a) Randomized controlled trial evaluating dialkylcarbamoyl chloride impregnated dressings for the prevention of surgical site infections in adult women undergoing caesarean section. Surgical Infections (Larchmt) 17(4): 427 -35.
  2. Bua N, et al. Dialkylcarbamoyl Chloride Dressings in the Prevention of Surgical Site Infections after Nonimplant Vascular Surgery. Ann Vasc Surg. 2017 Oct:44:387-392.
  3. Andersson R et al. Surgical Infections and Antibiotic Stewardship: In Need for New Directions. Scandinavian Journal of Surgery. 2021 Mar; 110(1):110-112
  4. Sartelli M, et al. Antimicrobial Stewardship: A Call to Action for Surgeons. Surg Infect (Larchmt). 2016 Dec; 17(6):625-631
  5. Getting It Right First Time. GIRFT SSI National Survey. 2019. https://gettingitrightfirsttime.co.uk/wp-content/uploads/2017/08/SSI-Report-GIRFT-APRIL19e-FINAL.pdf
  6. Anderson D, et al. Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update. Infect Control Hosp Epidemiol. 2014 Jun;35(6):605-27
  7. Bua. N et al. 2017 Dialkylcarbamoyl Chloride (DACC) Dressings in the Prevention of Surgical Site Infections After Non-implant Vascular Surgery: Annals of Vascular Surgery; 44: 387–392 dx.doi.org/10.1016/j.avsg.2017.03.198 2017 Elsevier Inc. All rights reserved. Manuscript received: October 11, 2016
  8. National Institute for Health and Care Excellence (NICE). (2021). State of the Nation: Surgical Site Infections. NICE.

*© NICE 2021 Leukomed Sorbact for preventing surgical site infection.
Available from www.nice.org.uk/guidance/mtg55. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Author

Ashley Clydesdale
Brand Manager – Essity UK Ltd